Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah looks like we are headed to the next level
AMRS is not a joke...it has the possibility to be huge....as we near the 3rd qtr report of RECORD REVENUES and forward looking progress we may soar anytime...again imo AMRS is not a joke....we consolidated for days...now looks like we are breaking through...
getting ready to break through to higher levels
guys looks like we could have the breakthrough
Bought me some of that ...saw it getting ready to move higher so i thought i better get in now....thx
really executing that bid today...over 100k at .593
there went the 30k shares at .593
i saw it sitting there
as you can see the bid is the one mostly being executed so far today...
whoever has all the shares to sell hopefully runs out soon....so far the bid is taken out rather easily....this fund or institution could be locking in profits for the end of the year....at some point there has to be a reason for someone to move us through this resistance at .60....when we try they flood the offers and we dont have enough momentum to carry us through it....
Paying close attention...appears someone doesnt want AMRS over .60 at this time.....so we should break through .60 at some point or breakdown to support...I dont expect this to continue at this level for long....
I just looked at that order i was talking about and it was dated 9/21 and called a confidential treatment order....and they can work either way...meaning that someone can buy the stock and not want people to know who bought it for special reasons......and someone can file for the same treatment if they want to sell the stock because it had underperformed but did not want that to be made public for certain reasons and they file the petition for the CT order...
I expected all day that day to see someone commenting on this board about it and they didnt.....
all i know is...is that we took off from .40 (that is when it caught my attention) to where we hit .63 yesterday...I actually believe the move up started in the .30's or so but I wasnt here then....missed that a few days...dog gone it...because this was definitely goooood money.....and i am hoping we get both the news and support to take this thing to 1.00 and over in the coming days...before the end of the year...
Now in response to your post....
What I said is exactly what I meant...we have went up significantly but we trade like we have 400,000,000,000 yes billion in the float...
I expect to see a spike in price at least in one day...meaning the stock was so strong that the offers at the lower prices would withdraw but instead they keep piling it on.....it makes me think some fund or at least someone who owns a lot of this stock is selling it...but on the other hand we have some very very strong support that comes in and takes them out..
There was a large player that filed a report the other day but it was liste as SPECIAL OR CONFIDENTIAL...Now that could have been when the turnaround started....I watched it at .40 when very signifcant support began lifting this stock higher each and every day practically...yesterday at the close was the worse selling i have witnessed since i bought the stock...but again today around .57 that support rallied the stock in the face of a market sell off...
as we say "nothing goes straight up" but I didnt like the sell at the end of the day yesterday. I did see someone sitting at .57 will about 250k shares hoping for that to happen at the end of the day again so he could get taken out....but it didnt happen today....
as far as what i have read i see no worrying about AMRS cash situation...as far as I can tell they believe the deals they have signed since April will bring them through. Especially this year and for the big part and backend of their debt there seems to be a path to remedy that....especially with their becoming cash flow positive by the end of 2016 and the significant raise in revenues....but still you have to be smart and have your exit strategy and try to keep cash onhand
Well, no big sell off at the end of the day today like they did yesterday...
like i said before ...i do not believe anyone takes a position in a stock and then proceeds to be negative the stock...you do your DD first and anyone who buys....buys in hope of being rewarded...not the other way around....i buy and i sell just like others and try to keep cash on hand for dips...the trend was strong but nothing goes straight up....but no doubt about this one, there are definitely some strong forces buying and selling the stock....and I dont understands exactly what is going on...i just look for the trends...trends have to do with buyers,sellers and whether the market is positive or negative over a period of time
IS IT TRUE
that on 9/19 your created your alias and said the following
You people keep posting that the stock is really going to pop and it doesn't and the volume is only slightly above average so I'm not sure why you keep saying this-- sounds like a lot of pumping to me. I hope it does go up but I don't see any convincing evidence. GLTA!
regardless now of whether the stock goes up or down you missed out on the move you did not believe would happen....have a good day
Is it true what AMRS said about RECORD REVENUES FOR THE 3RD QTR
Is it true THEY WILL BE CASH FLOW POSITIVE BY OR BEFORE THE END OF 2016..
This web based, fully extensible, design software, available under an open source license...
Just letting you know this is licensed software...
Autodesk just had 552 million in revs for the last qtr...they dont need pocket change, they are huge. So another avenue for License fees..
Amrs is getting it done and are in high gear for the 2nd half of the year and int 2017
AMRS is clearly playing with the big boys
NEWS...now they are teaming up with AUTODESK and making presentation today
Analyst Reports
Search News
Search
Article Tools
Set News Alert
Companies Mentioned
Symbol
Last
Change
ADSK
$71.18
0.00%
AMRS
$0.60
0.00%
Back to Search Results
Amyris and Autodesk Offer Powerful Open Source Tools for Genetic Design to Enable Rapid DNA Engineering
Today 8:30 AM ET (GlobeNewswire)Print
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, in collaboration with the Autodesk BioNano Research Group, today announced the immediate availability of powerful open source tools for genetic design that leverage Autodesk's Genetic Constructor, an extensible, open source, cloud CAD tool, and Amyris's open source Genotype Specification Language ("GSL"), to more rapidly drive biological design and complex DNA construction. Autodesk BioNano Research and Amyris will be showcasing this solution today at SynBioBeta SF 2016 in San Francisco.
Best of Both Worlds
Those working in the genetic design community traditionally use a collection of disparate industrial and academic software tools that can be inefficient, difficult to acquire, set up, learn, and use. Genetic Constructor with GSL inside provides a seamless environment combining the power of a written genetic programming language along with an intuitive graphical environment. In the same way that early compilers in the software industry dramatically increased productivity and standardized the field, we expect that enabling everyone to access industrial grade tooling will greatly advance the synthetic biology sector. Industry wide adoption of an efficient common tool set and genetic programming language will benefit everyone.
"Amyris is clearly a leader in high-throughput DNA manufacturing. We are thrilled to enable any biologist to use GSL to 'code' their biological designs and we hope Genetic Constructor plus GSL dramatically speeds up the pace of genetic design," stated Eli Groban, Head of BioNano Research at Autodesk.
"We are extremely pleased that Autodesk BioNano Research has adopted GSL as the first integration of a language for genomic design," said Joel Cherry, President of Research & Development at Amyris. "Amyris used its deep experience designing DNA to develop a common-sense language for describing genetic designs. Building on notation that is familiar to any geneticist, the GSL compiler translates a request quickly into the information needed to create the DNA."
Continued Cherry, "Much as standardized computer languages like C revolutionized the early computer industry, we hope to establish GSL as a common industry standard platform. Genetic Constructor is the perfect visual complement to GSL."
Genetic Constructor Plus GSL - Free Powerful Open Source Tool Set for Genetic Design
Genetic Constructor started from a collaboration between the Autodesk BioNano Research group and the University of Edinburgh. Autodesk's BioNano Research Group aims to place the full power of Autodesk software in the hands of scientists, thereby enabling the ability to design on the BioNano scale. This web based, fully extensible, design software, available under an open source license, now incorporates an extension featuring an integrated development environment that is easier for scientists to use in the real-world process of assembling and testing actual, physical DNA coupled with Amyris's GSL.
Genotype Specification Language (GSL), is a programming language that facilitates the rapid design of large and complex DNA constructs used to engineer genomes. The GSL compiler implements a high-level language based on traditional genetic notation, as well as a set of low-level DNA manipulation primitives. The language allows facile incorporation of parts from a library of cloned DNA constructs and from the "natural" library of parts in fully sequenced and annotated genomes. GSL was designed to engage genetic engineers in their native language while providing a framework for higher level abstract tooling. GSL was developed and open sourced by Amyris.
the great news is the trend line continues to be supported...we are in a slow and deliberate move to 1.00...there are really a few big funds or institutions involved with this move.....slow and steady uptrend is good..however i still look for that sudden spike.....nothing but good news ahead and a great 3rd qtr release coming first part of November...that should really move us along....when AMRS gets in the 1.00 range then those funds which are prohibited from buying under 1.00 can pick this thing up and move us much higher..............it can happen
higher highs and higher lows means a higher trending stock...actually claytrader chart is correct...the resistance has become our new support.........barring anymore good news that is, and if that is the case then who knows how high....we certainly have great news ahead of us, which in and of itself lends higher support levels as we move along.....
wow @ 16:02:59 909,400 shares for .6061.....someone is accumulating throughout the day...putting in an order and getting it filled....so somewhere I am looking for AMRS to take off.....things are moving in this stock....somebody putting the orders in.......imo...when they take it up we begin to fly....................................................
there are people who wait to see what warren buffet buys and then they go and do the same and ride his buys...well in this case we have funds buying in and someone really supporting the stock....i say do as they do and RIDE THE WAVE....you know those who do the warren buffet thing are really not wrong....
they continue to accumulate this stock...imo they will get AMRS t 1.00 and over...they have reasons to do it...then other funds came begin to buy the stock and that is how you get to higher price targets..some funds cannot buy into stocks below 1.00...imo thse people will get us there...RIDE THE WAVE...
I'll add one more thing to the previous post...
plus they will report record revenues for the 3rd qtr ...plus be cash flow positive before or by years end....
so if this had been one of those biotech stocks i can imagine it would have went through the stratosphere...i believe ARMS except just not that fast...unless they turn it loose at some point...
with that being said..when the funds and institutions take it up at least these penny stock boys will not be able to bring it down...and that is a goooooood thing....a lot of accumulation going on....
If some of these biotech stocks had announced they had rec'd 30million in financing plus and investment in the company by the financier along with using their facilities plus sharing in the revenues the stock would probably have went ballistic..as it stands now there are some institutions and funds controlling AMRS...individuals like us are not playing the part in this that is going on right now...but when the time comes and someone gets the upper hand you will see the move...no doubt someone will be happy and someone will be left behind..but we can buy the dips just like they are...so here is hoping to be between .63/.66 by the close.......
there are big funds in AMRS. I believe we will move to 1.00 and over..but these funds and institutions are the ones that will take us there...RIDE THE WAVE....buy the dips...imo this stock is heading up and up....I can see nothing but good news in its future...it would not surprise me if it were just a short cycle before more news is released...AMRS is a hot commodity right now...alot of big names cannot afford to be left behind...
I would refer to this as catching the wave...the wave to 1.00 imo...
going to be interesting to see which new funds took positions in AMRS and which ones added to their positions...and should really get interesting as we begin to near the quarterly release...not even to mention 2017...would really expect the funds to add in this 3rd qtr before they lock in their profits for the year...so we should see the movement in this 3rd qtr for sure...i really expect them to lift AMRS to 1.00 and over this qtr...we got the big companies putting their money behind AMRS to make sure they are successful....and that should really put the cream on top of AMRS outlook going forward...I look for more of those press releases as we saw Friday..
By the way myopinion...you can tell by the movement in the stock (the way it trades) that there are some big forces moving in AMRS and as 1.00 begins to look more likely I expect it to hit 1.00 and then over....at that time it will be obvious people will miss out as the funds that have interest in AMRS succeeding move this one on up....
Hey, myopinion....keep a watch out for the upgrades in the coming days if you dont mind...I dont know your access but I appreciate your post...I will try to do the same...
Man it is great to be in on a real winner...and this one hasnt even broke out yet...wow
The big players get in when they smell MONEY...I expect some upgrades and new articles coming out....looking for 1.00 and over...Fridays announcement I think is a clincher for AMRS as a major player in this sector...
Some of those who added shares in the 2nd qtr....
A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Amyris during the first quarter valued at approximately $269,000. Finally, Geode Capital Management LLC increased its stake in Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares during the period. 35.68% of the stock is currently owned by institutional investors.
Some big forces at play on AMRS...going to be nice to find the new ones who entered this last quarter and those who added more...imo it is evident someone is
One of todays releases for this segment. Notice AMRS listed as one of the main players in this market
10-03-2016 02:44 PM CET - Health & Medicine
Print PDF
Global Synthetic Biology Market Trends, Size, Share, Growth and Demand Forecast to 2020
Press release from: P&S Market Research
The global synthetic biology market was valued at $3,933.9 million in 2014, and it is expected to grow with a CAGR of 35.4% during the period 2015 - 2020. The global synthetic biology market is growing, due to increasing support from government organizations, and growing geriatric population. In addition, the innovative and advanced applications of synthetic biology, increasing research activities, and increasing R&D investments in drug discovery and development are also supporting the growth of this market.
Explore More About “Global Synthetic Biology Market” at: www.psmarketresearch.com/market-analysis/synthetic-biolog...
On the basis of type of segment, the technology segment is expected to be the largest market and would witness fastest growth during the forecast period. Among the application segment, pharmaceutical and diagnostic had the largest market size in the global market in 2014.
The increasing support from government organizations and growing geriatric population are playing a pivotal role in the growth of this market. Some of the major organizations include National Science Foundation (NSF), National Aeronautics and Space Administration (NASA), Centre for Chemical and Synthetic Biology (CCSB), Synthetic Biology Engineering Research Center (SynBERC), and International Association Synthetic Biology (IASB). These organizations are providing support in form of funding, and initiatives implemented by them for basic and applied research with their respective goals.
Explore Report Sample at: www.psmarketresearch.com/market-analysis/synthetic-biolog...
Additionally, the innovative and advanced applications of synthetic biology, increasing research activities, and increasing R&D investments in drug discovery and development are also supporting the growth of this market. However stringent regulatory requirements, expensive research procedures, and harmful effects of synthetic biology act as hindrance in the growth of the global market. The growing number of mergers and acquisitions is one of the latest trends observed in this market.
Geographically, North America dominated the global market, among all the regions in 2014; and it is expected to grow with a CAGR of 35.2% during the period 2015 – 2020. However, the Asian market is expected to witness fastest growth, with a CAGR of 39.8% during the forecast period.
Browse Related Research: www.psmarketresearch.com/industry-report/healthcare
The key companies operating in the global synthetic biology market include E. I. du PONT de Nemours and Company, Amyris Inc., GenScript USA Inc., Intrexon Corporation, Thermo Fisher Scientific Inc., Synthetic Genomics Inc., Royal DSM, Novozymes A/S, New England Biolabs Inc., and Integrated DNA Technologies Inc.
It would probably be a wise thing to slowly read the press release for Friday..and read it slowly so you comprehend what is being said..I am sure the analyst will but here is the last paragraph from one of the releases:
Amyris now expects 2017 revenue for the first targeted product of around $40 million and anticipated revenues from the expanded partnership are expected to average over $70 million annually beyond 2017. This expansion is expected to lead to the second molecule to be supplied by Amyris in 2019 into a market that is approximately the same size as the first agreement. These agreements demonstrate the leadership position of Amyris as the only company in industrial biotechnology to produce multiple molecules at a single industrial fermentation facility and with one of the strongest contracted product pipelines in the sector.
Get that last sentence
with one of the strongest contracted product pipelines in the sector.
Make no mistake, AMRS is now on a lot of stock screens...
I looking forward to news analyst initiating coverage of AMRS with new price targets as well as new articles on AMRS going to press.
In case you missed it...that news Friday came at the end of the 3rd qtr and can be an addition to their already RECORD REVENUE 3rd qtr..just in case you may have wondered why the news Friday...
These large mega companies doesn't hand out millions of dollars like candy...they are in a race to be on top of this new revenue stream and AMRS has the CODE to produce the material....
This would put them in the crosshairs as a buyout potential going into 2017. That is my opinion but I don't think it is just wishful thinking...Biogen, JNJ and the other big names are trying to gain the upper hand quickly because it has so much potential..
In this press release Friday the name of the company was not released for COMPETITIVE purposes....none of the big corps wants to be left behind on this new bio revolution...
October 2, 2016 | Jim Lane
Tweet
Share
Mail
Share
The Digest Bioeconomy Index, an index of publicly traded advanced bioeconomy stocks, gained 1.14 percent to 56.85 as advanced bio surged. For the day, Deinove (ALDEI.PA) dumped 13.84 percent to $2.66, while Metabolix (MBLX) rocketed up 12.79 percent to $0.45 . Among other equities, Amyris (AMRS) soared 14.98 percent to $0.58
If analyst was a little hesitant before Fridays press release I expect more of them to be convinced now...and its a new technology with lots of applications and future dollar projections are high